{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"AKTX","limit":50},"count":50,"signals":[{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":", our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our indu","filed_date":"2026-03-30","accession":"0001493152-26-013664","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013664.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":44,"context":"of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug or biologic may be marketed in the U.S. generally involves the following: |  |  |  completion of preclinical laboratory tests, animal studies and","filed_date":"2026-03-30","accession":"0001493152-26-013664","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013664.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"nvestor Relations Corporate Governance section of our website, which is located at www.akaritx.com. | 84 | | **Compensation Committee** Our compensation committee currently consists of three members, appointed by the board of directors: Mr. Neal (Chair), Mr. Patel, and Mr. Bazemore, all of whom are independent within the meaning of SEC corporate governance rules of independence for purposes of the compensation committee. The Board","filed_date":"2026-03-30","accession":"0001493152-26-013664","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013664.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":15,"context":"ne months ended September 30, 2024 were $1 million and $2.3 million, respectively. No such costs were incurred during three and nine months ended September 30, 2025. **Restructuring and other costs** Restructuring costs consist primarily of severance and related benefit costs related to workforce reductions incurred in connection with the reduction in force (RIF), which the Company began to implement in May 2024. Re","filed_date":"2026-01-23","accession":"0001493152-26-003458","full_text":"https://origin.rootz.global/static/filing/0001493152-26-003458.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"ble to commercialize our product candidates or any of our future product candidates on a timely basis or at all. | | |  |  |  | | |  |  |  We may encounter substantial delays in the commencement, enrollment or completion of clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product","filed_date":"2026-01-23","accession":"0001493152-26-003458","full_text":"https://origin.rootz.global/static/filing/0001493152-26-003458.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"rrent product candidates or any of our other future product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval, which would have a significant adverse impact on our business and results of operations. | 14 | | **Our employees, independent contractors, principal investigators, contract research organizations, consultants, vendors and collaboration partners","filed_date":"2026-01-23","accession":"0001493152-26-003458","full_text":"https://origin.rootz.global/static/filing/0001493152-26-003458.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"n the Investor Relations - Corporate Governance section of our website, which is located at www.akaritx.com. **Compensation Committee** Our compensation committee currently consists of three members, appointed by the board of directors: Mr. Neal (Chair), Mr. Patel, and Mr. Bazemore, all of whom are independent within the meaning of SEC corporate governance rules of independence for purposes of the compensation committee. The Board","filed_date":"2026-01-23","accession":"0001493152-26-003458","full_text":"https://origin.rootz.global/static/filing/0001493152-26-003458.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"ns the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors, officers, and 10% and greater stockholders of the Company, in the form of Exhibit B attached hereto. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). | 3 | | | | | Ordinary Share(s) means the ordinary sha","filed_date":"2025-10-16","accession":"0001493152-25-018269","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018269.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"mpanys hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) program with investigational nomacopan was suspended. The reduction-in-force was part of an operational restructuring plan (the May 2024 Restructuring Plan) which also included the elimination of certain senior management positions. The May 2024 Restructuring Plan was completed in the third quarter of 2024. The purpose o","filed_date":"2025-08-13","accession":"0001641172-25-023569","full_text":"https://origin.rootz.global/static/filing/0001641172-25-023569.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":41,"context":"Equity Incentive Plan (the 2014 Plan), to the extent such awards are forfeited or cancelled, or expire unexercised. | | |  13. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers (NEOs) as disclosed in the Proxy Statement. | | |  14. | To approve the time-vested one time grant stock option awards over 225,000 ADSs (representing 450,000,000 ordinary shares) granted, condition","filed_date":"2025-06-06","accession":"0001641172-25-014023","full_text":"https://origin.rootz.global/static/filing/0001641172-25-014023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":", our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our indu","filed_date":"2025-04-15","accession":"0000950170-25-054278","full_text":"https://origin.rootz.global/static/filing/0000950170-25-054278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug or biologic may be marketed in the U.S. generally involves the following: completion of preclinical laboratory tests, animal studies and formulati","filed_date":"2025-04-15","accession":"0000950170-25-054278","full_text":"https://origin.rootz.global/static/filing/0000950170-25-054278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"ound in the Investor Relations Corporate Governance section of our website, which is located at www.akaritx.com. Compensation Committee Our compensation committee currently consists of three members, appointed by the board of directors: Mr. Neal (Chair), Mr. Patel, and Mr. Bazemore, all of whom are independent within the meaning of SEC corporate governance rules of independence for purposes of the compensation committee. The Board","filed_date":"2025-04-15","accession":"0000950170-25-054278","full_text":"https://origin.rootz.global/static/filing/0000950170-25-054278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"ts shall have the meaning ascribed to such term in Section 3.1(p).  Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.  Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b).  Material Permits shall have the meaning ascribed to such term in Section 3.1(n).  Money Laundering Laws shall have the meaning ascribe","filed_date":"2025-03-03","accession":"0001193125-25-043544","full_text":"https://origin.rootz.global/static/filing/0001193125-25-043544.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":", our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our indu","filed_date":"2024-08-19","accession":"0000950170-24-098576","full_text":"https://origin.rootz.global/static/filing/0000950170-24-098576.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ality standards set forth in the Merger Agreement), (vii) compliance by the other party in all material respects with such other partys obligations under the Merger Agreement; (viii) the absence of a material adverse effect on the other party, (ix) the other partys net cash being greater than negative $13.5 million and (x) the PIPE Investment (as defined in the Merger Agreement) shall have been consummated simultaneousl","filed_date":"2024-08-19","accession":"0000950170-24-098576","full_text":"https://origin.rootz.global/static/filing/0000950170-24-098576.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ing ascribed to such term in Section 3.1(p). &#x201c;Liens&#x201d; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. &#x201c;Material Adverse Effect&#x201d; shall have the meaning ascribed to such term in Section 3.1(b). &#x201c;Material Permits&#x201d; shall have the meaning ascribed to such term in Section 3.1(n).  &#x201c;Money Laundering Laws","filed_date":"2024-06-04","accession":"0000950170-24-068304","full_text":"https://origin.rootz.global/static/filing/0000950170-24-068304.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"2015 through December 2022. Effective January 1, 2023. Dr. Prudo began serving as the Chairman of our Board of Directors with a renumeration package of $100,000 per annum, paid in equal monthly installments. (4) Mr. Hashad was appointed to our Board of Directors effective June 30, 2023, at our 2023 annual general meeting. Mr. Hashad has served as a member of our audit committee and nominating and co","filed_date":"2024-06-03","accession":"0001104659-24-067797","full_text":"https://origin.rootz.global/static/filing/0001104659-24-067797.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"eholders. 10. To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors remuneration. 11. To approve, on a non-binding, advisory basis, the compensation of our named executive officers (NEOs) as disclosed in this Proxy Statement. 12. To indicate, on a non-binding, advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of Akaris NEOs. Pursu","filed_date":"2024-06-03","accession":"0001104659-24-067797","full_text":"https://origin.rootz.global/static/filing/0001104659-24-067797.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":", our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our indu","filed_date":"2024-03-29","accession":"0000950170-24-038661","full_text":"https://origin.rootz.global/static/filing/0000950170-24-038661.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":50,"context":"ality standards set forth in the Merger Agreement), (vii) compliance by the other party in all material respects with such other partys obligations under the Merger Agreement; (viii) the absence of a material adverse effect on the other party, (ix) the other partys net cash being greater than negative $13,500,000 and (x) the PIPE Investment (as defined in the Merger Agreement) shall have been consummated simultaneously","filed_date":"2024-03-29","accession":"0000950170-24-038661","full_text":"https://origin.rootz.global/static/filing/0000950170-24-038661.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"eutics Plc, Kira Biotech  86 Pty Ltd., and Envisagenics, Inc. Mr. Grissinger holds a B.Sc. in Chemistry from Juniata College and an MBA from Temple University, Fox School of Business. Wael Hashad was appointed to our board of directors in June 2023. Mr. Hashad currently serves as CEO of Longeveron, Inc. (Nasdaq: LGVN), a U.S. clinical-stage biotechnology company developing regenerative medicines for rare pediatric diseases, aging-","filed_date":"2024-03-29","accession":"0000950170-24-038661","full_text":"https://origin.rootz.global/static/filing/0000950170-24-038661.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). 2 Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribe","filed_date":"2024-03-11","accession":"0001104659-24-033087","full_text":"https://origin.rootz.global/static/filing/0001104659-24-033087.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"d safety for nomacopan; | | | | | we do not know the degree to which nomacopan will be adopted by the market, even if approved; | | | | | in our clinical programs, we may experience difficulty in enrollment, adjustments to clinical trial protocols or the need for additional clinical trial sites, which could delay our clinical trial progress; | | | | | our reliance on a sole manufacturer to supply dru","filed_date":"2023-05-01","accession":"0001410578-23-000848","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"our consolidated financial statements. If we discover errors in our financial statements and are required to restate in the future, it could create additional risks and uncertainties that may have a material adverse effect on our business, financial position and results of operations. | | | | If we fail to develop and commercialize other product candidates, we may be unable to generate revenues. | | | | Our business ei","filed_date":"2023-05-01","accession":"0001410578-23-000848","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"do served as Executive Chairman of our board of directors from September 2015 until December 2022, and assumed the role of Chairman of the Board effective January 1, 2023. | | | (5) | Ms. Jacques was appointed our President and Chief Executive Officer in March 2022. Ms. Jacques received a sign-on bonus in the amount of $650,000. | | | (6) | Mr. Richardson resigned as Chief Executive Officer and Chief Operating Officer in March 20","filed_date":"2023-05-01","accession":"0001410578-23-000848","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"d safety for nomacopan; | | | | | we do not know the degree to which nomacopan will be adopted by the market, even if approved; | | | | | in our clinical programs, we may experience difficulty in enrollment, adjustments to clinical trial protocols or the need for additional clinical trial sites, which could delay our clinical trial progress; | | | | | our reliance on a sole manufacturer to supply dru","filed_date":"2022-05-16","accession":"0001410578-22-001546","full_text":"https://origin.rootz.global/static/filing/0001410578-22-001546.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"our consolidated financial statements. If we discover errors in our financial statements and are required to restate in the future, it could create additional risks and uncertainties that may have a material adverse effect on our business, financial position and results of operations. | | | | If we fail to develop and commercialize other product candidates, we may be unable to generate revenues. | | 6 [Table of Content","filed_date":"2022-05-16","accession":"0001410578-22-001546","full_text":"https://origin.rootz.global/static/filing/0001410578-22-001546.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":11,"context":"a 401K plan or pension scheme and amounts accrued for paid leave. | | | (3) | Mr. Richardson resigned as Chief Executive Officer and Chief Operating Officer in March 2022. | | | (4) | Dr. Hombeck was appointed as our Chief Financial Officer in June 2020. | | Narrative Disclosure to Summary Compensation Table *Ray Prudo*. On September21, 2015, in connection with the Acquisition, we entered into an agreement with our Executive Chairman an","filed_date":"2022-05-16","accession":"0001410578-22-001546","full_text":"https://origin.rootz.global/static/filing/0001410578-22-001546.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ty for nomacopan; | | |  |  |  we do not know the degree to which nomacopan will be accepted as a therapy, even if approved; | | |  |  |  in our clinical programs, we may experience difficulty in enrollment, variability in patients, adjustments to clinical trial procedures and the need for additional clinical trial sites, which could delay our clinical trial progress; | | |  |  |  our reliance on a s","filed_date":"2021-04-21","accession":"0001104659-21-052672","full_text":"https://origin.rootz.global/static/filing/0001104659-21-052672.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"y to protect our intellectual property and our proprietary technologies. | | |  | | Others may claim an ownership interest in our intellectual property, which could expose it to litigation and have a significant adverse effect on its prospects. | | **Risks Related to our Business Operations** |  | | Our business either directly or indirectly through critical suppliers to Akari may be adversely affected by the impact of cor","filed_date":"2021-04-21","accession":"0001104659-21-052672","full_text":"https://origin.rootz.global/static/filing/0001104659-21-052672.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":11,"context":"or the years ended December 31, 2020 and 2019. | | |  |  (2) |  Consists of company contributions to a 401K plan or pension scheme and amounts accrued for paid leave. | | |  |  (3) |  Dr. Hombeck was appointed as our Chief Financial Officer in June 2020. | | 73 **Narrative Disclosure to Summary Compensation Table** *Ray Prudo*. On September 21, 2015, in connection with the Acquisition, we entered into an agreement with our Executive Cha","filed_date":"2021-04-21","accession":"0001104659-21-052672","full_text":"https://origin.rootz.global/static/filing/0001104659-21-052672.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ty for nomacopan; | | |  |  |  we do not know the degree to which nomacopan will be accepted as a therapy, even if approved; | | |  |  |  in our clinical programs, we may experience difficulty in enrollment, variability in patients, adjustments to clinical trial procedures and the need for additional clinical trial sites, which could delay our clinical trial progress; | | |  |  |  our reliance on a s","filed_date":"2020-03-31","accession":"0001104659-20-040722","full_text":"https://origin.rootz.global/static/filing/0001104659-20-040722.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ent who withdrew from the trial on day 43 also did not meet the primary endpoint. If nomacopan does not demonstrate adequate efficacy, its development may be delayed or terminated, which could have a material adverse effect on our financial condition and results of operation. 8 ** ** **Results of earlier preclinical studies or clinical trials may not be predictive of advancement to the next phase of development.** Compl","filed_date":"2020-03-31","accession":"0001104659-20-040722","full_text":"https://origin.rootz.global/static/filing/0001104659-20-040722.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"| |  |  (2) |  Consists of company contributions to a 401K plan or pension scheme. | | |  |  (3) |  Mr. Elefant resigned as Chief Financial Officer in September 2019. | | |  |  (4) |  Dr. Solomon was appointed as our Chief Executive Officer on August 28, 2017 and resigned as Chief Executive Officer on May 8, 2018. | | |  |  (5) |  Consists of $1,000 per month allowance. See Item 6 B. Directors, Senior Management and EmployeesCompensatio","filed_date":"2020-03-31","accession":"0001104659-20-040722","full_text":"https://origin.rootz.global/static/filing/0001104659-20-040722.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"Coversin); | | |  | | we do not know the degree to which Nomacopan (Coversin) will be accepted as a therapy, even if approved; | | |  | | in our clinical programs, we may experience difficulty in enrollment, variability in patients, adjustments to clinical trial procedures and the need for additional clinical trial sites, which could delay our clinical trial progress; | | |  | | our reliance on a sol","filed_date":"2019-04-23","accession":"0001144204-19-020749","full_text":"https://origin.rootz.global/static/filing/0001144204-19-020749.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"hdrew from the trial on day 43 also did not meet the primary endpoint. If Nomacopan (Coversin) does not demonstrate adequate efficacy, its development may be delayed or terminated, which could have a material adverse effect on our financial condition and results of operation. | 8 | | ** ** **Results of earlier preclinical studies or clinical trials may not be predictive of advancement to the next phase of development.**","filed_date":"2019-04-23","accession":"0001144204-19-020749","full_text":"https://origin.rootz.global/static/filing/0001144204-19-020749.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"ded in our Annual Report on Form 20-F for the years ended December 31, 2018 and 2017. | | |  | (2) | Consists of company contributions to a 401K plan or pension scheme. | | |  | (3) | Dr. Solomon was appointed as our Chief Executive Officer on August 28, 2017 and resigned as Chief Executive Officer on May 8, 2018. | | |  | (4) | Consists of (i) $193,750 in 2017 in interim housing and related expenses paid on behalf of Dr. Solomon, and (","filed_date":"2019-04-23","accession":"0001144204-19-020749","full_text":"https://origin.rootz.global/static/filing/0001144204-19-020749.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"fety for Coversin; | | |  |  |  we do not know the degree to which Coversin will be accepted as a therapy, even if approved; | | |  |  |  in our clinical programs, we may experience difficulty in enrollment, variability in patients, adjustments to clinical trial procedures and the need for additional clinical trial sites, which could delay our clinical trial progress; | | |  |  |  our reliance on a s","filed_date":"2018-07-18","accession":"0001144204-18-038891","full_text":"https://origin.rootz.global/static/filing/0001144204-18-038891.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ent that withdrew from the trial on day 43 also did not meet the primary endpoint. If Coversin does not demonstrate adequate efficacy, its development may be delayed or terminated, which could have a material adverse effect on our financial condition and results of operation. **Results of earlier preclinical studies or clinical trials may not be predictive of advancement to the next phase of development.** Completion of","filed_date":"2018-07-18","accession":"0001144204-18-038891","full_text":"https://origin.rootz.global/static/filing/0001144204-18-038891.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"al Report on Form 20-F for the years ended December 31, 2017 and 2016. |  | | | 59 | | | |  | (2) | Consists of company contributions to a 401K plan or pension scheme. |  | |  | (3) | Dr. Solomon was appointed as our Chief Executive Officer on August 28, 2017 and resigned as Chief Executive Officer on May 8, 2018. |  | |  | (4) | Consists of (i) $193,750 in interim housing and related expenses paid on behalf of Dr. Solomon, and (ii) $1,","filed_date":"2018-07-18","accession":"0001144204-18-038891","full_text":"https://origin.rootz.global/static/filing/0001144204-18-038891.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"e can be no assurance that it will have its expected efficacy in these conditions. If Coversin does not demonstrate adequate efficacy, its development may be delayed or terminated, which could have a material adverse effect on our financial condition and results of operation. **The route of administration or dose for Coversin may be inadequate.** ** ** Unsatisfactory drug availability due to problems relating to the rou","filed_date":"2017-03-31","accession":"0001144204-17-018167","full_text":"https://origin.rootz.global/static/filing/0001144204-17-018167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":11,"context":"ng grant date fair value may be found in our Financial Statements, included in our Annual Report on Form 20-F for the years ended December 31, 2016 and 2015. | | | | 45 | | | |  | (2) | Dr. Prudo was appointed as our Executive Chairman in connection with the Acquisition. | | |  | (3) | Mr. Richardson was appointed as our Chief Operating Officer in connection with the Acquisition. | | |  | (4) | Mr. Shaw was appointed as our General","filed_date":"2017-03-31","accession":"0001144204-17-018167","full_text":"https://origin.rootz.global/static/filing/0001144204-17-018167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug or biologic may be marketed in the U.S. generally involves the following: |  |  |  completion of preclinical laboratory tests, animal studies and","filed_date":"2016-03-23","accession":"0001144204-16-089697","full_text":"https://origin.rootz.global/static/filing/0001144204-16-089697.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"e can be no assurance that it will have its expected efficacy in these conditions. If Coversin does not demonstrate adequate efficacy, its development may be delayed or terminated, which could have a material adverse effect on our financial condition and results of operation.  31  **The route of administration or dose for Coversin may be inadequate.** ** ** Unsatisfactory drug availability due to problems relating to th","filed_date":"2015-11-23","accession":"0001144204-15-067423","full_text":"https://origin.rootz.global/static/filing/0001144204-15-067423.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"eases in third-party reimbursement for our product candidates or a decision by a third-party payer to not cover our product candidates could reduce physician usage of the product candidate and have a material adverse effect on our sales, results of operations and financial condition. We expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the","filed_date":"2015-02-11","accession":"0001144204-15-007770","full_text":"https://origin.rootz.global/static/filing/0001144204-15-007770.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"ilure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval would impair our ability to develop foreign markets for our product candidates and may have a material adverse effect on our results of operations and financial condition. ** ** **Both before and after marketing approval, our product candidates are subject to ongoing regulatory requirements, and if we fail to comply","filed_date":"2014-03-24","accession":"0001144204-14-017308","full_text":"https://origin.rootz.global/static/filing/0001144204-14-017308.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ilure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval would impair our ability to develop foreign markets for our product candidates and may have a material adverse effect on our results of operations and financial condition. **Both before and after marketing approval, our product candidates are subject to ongoing regulatory requirements, and if we fail to comply with","filed_date":"2013-03-22","accession":"0001144204-13-016759","full_text":"https://origin.rootz.global/static/filing/0001144204-13-016759.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"ct, who is known by us to own beneficially more than 5% of the issued and outstanding shares of our ordinary shares; | | |  |  | | |  |  each of our current directors; | | |  |  | | |  |  each of our named executive officers; | | |  |  | | |  |  all of our current directors and executive officers as a group. | | We have determined beneficial ownership in accordance with the rules of the SEC, and the information in the t","filed_date":"2025-11-17","accession":"0001493152-25-023911","full_text":"https://origin.rootz.global/static/filing/0001493152-25-023911.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AKTX","company":"Akari Therapeutics Plc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"d safety for Coversin; | | |  | | we do not know the degree to which Coversin will be accepted as a therapy, even if approved; | | |  | | in our clinical programs, we may experience difficulty in enrollment, variability in patients, adjustments to clinical trial procedures and the need for additional clinical trial sites, which could delay our clinical trial progress; | | |  | | our reliance on a sol","filed_date":"2017-03-31","accession":"0001144204-17-018167","full_text":"https://origin.rootz.global/static/filing/0001144204-17-018167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"dd6e17ec9e9da8e47ad693b0d700aaa6ba0614826284756e2a13c26c9ed9aa9b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e5b58ad6adbfa7988835d04946718b4083bab17c02290e92b3235614aea556aa","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":8,"hourly_limit":500,"remaining":492,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}